Product
CP-506
1 clinical trial
2 indications
Indication
solid tumorIndication
Protocol SpecificClinical trial
Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICIStatus: Recruiting, Estimated PCD: 2026-02-01